These results demonstrate that knocking down ST6GalNAc-I expression is effective in restoring gal-3-binding, gal-3 cell surface expression and in increasing cisplatin sensitivity in tumor cells. The gene discussed is ST6GALNAC1; the disease is neoplasm.